Deutsche Bank AG vs Humana Inc — how do they compare? Deutsche Bank AG trades at $33.61 (market cap $62.42B), while Humana Inc trades at $444.98 (market cap $47.61B). The key difference: Deutsche Bank AG is the larger of the two by market cap, and Deutsche Bank AG pays the higher dividend (3.46%). Which is the better fit depends on your goals — on Pluang, investors hold Deutsche Bank AG for 80 Days and Humana Inc for 53 Days on average.
| DB | HUM | |
|---|---|---|
Market Cap | $62.42B | $47.61B |
Volume | 2,918,760 | 1,827,332 |
Sector | Financials | Health |
52-Week High | $41.56 | $409.85 |
52-Week Low | $28.37 | $163.67 |
Typical Hold Time | 80 Days | 53 Days |
Enterprise Value | $77.06B | $54.97B |
Dividend Yield | 3.46% | 0.89% |
Signals from Pluang's Aura AI — not financial advice
Deutsche Bank (DB) trades at $33.55, down 4.5% amid concerns over Q3 investment banking revenue. The stock shows attractive valuation with P/E of 9.1 and P/B of 0.71, while fundamentals improved with 2025 net income reaching $6.93B. Technical indicators signal bearish momentum with price near support at $33. Recent news highlights management's focus on 2028 targets and wealth management growth.
The outlook remains mixed - strong fundamentals and undervaluation present opportunity, but near-term headwinds in investment banking and bearish technicals suggest caution. Key risks include revenue volatility and European economic pressures, while analyst consensus leans neutral with 57.6% hold ratings.
Humana (HUM) trades at $396.51, down 1.92% on the day, with strong technical momentum showing bullish moving averages and key support at $391. The company demonstrates consistent revenue growth reaching $129.7B in 2025, though net margins have compressed to 0.88%. Recent quarterly earnings have exceeded expectations, with Q2 2026 EPS of $7.61 beating estimates of $7.27. Analyst sentiment remains positive with a $432.63 consensus price target representing 9% upside potential from current levels.
The investment case centers on Humana's dominant Medicare Advantage position and consistent revenue growth, though margin pressure and regulatory scrutiny present headwinds. With 43% of analysts maintaining buy ratings and institutional accumulation continuing, the stock offers exposure to healthcare demographics but requires monitoring of enrollment trends and cost management execution.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →